Louisiana State Employees Retirement System Reduces Stake in DexCom, Inc. (NASDAQ:DXCM)

Louisiana State Employees Retirement System cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 7.0% in the fourth quarter, HoldingsChannel reports. The fund owned 49,500 shares of the medical device company’s stock after selling 3,700 shares during the period. Louisiana State Employees Retirement System’s holdings in DexCom were worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co lifted its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom in the third quarter valued at approximately $57,000. Finally, Covestor Ltd lifted its holdings in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock valued at $3,628,069 in the last three months. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on DXCM. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Royal Bank of Canada reduced their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

DexCom Trading Down 2.9 %

Shares of DXCM stock opened at $83.87 on Thursday. The stock’s fifty day moving average is $82.05 and its two-hundred day moving average is $75.13. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $32.76 billion, a P/E ratio of 50.22, a PEG ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.